Brigit Biofarmaka Teknologi Tbk. vs Reksa Dana Premier ETF IDX30 — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp236 (market cap 164.65B, 62.5K 24h volume), while Reksa Dana Premier ETF IDX30 trades at Rp460 (market cap 1.85T, 6.7K 24h volume). The key difference: Reksa Dana Premier ETF IDX30 is far larger — about 11.2× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Brigit Biofarmaka Teknologi Tbk. is more actively traded (62.5K versus 6.7K). Which is the better fit depends on your goals.
| OBAT | XIIT | |
|---|---|---|
Market Cap | 164.65B | 1.85T |
Volume | 62.5K | 6.7K |
Lot | 625 | 67 |
Turnover | 15.03M | 3.08M |
Average Price | 240.55 | 459.43 |
Value | 15.03M | 3.08M |
Indicative Equilibrium Price | 238 | — |
Indicative Equilibrium Volume | 100 | — |
Trailing returns across standard periods
Latest headlines on both assets
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →